A Study Comparing the Efficacy and Safety of ABT-652 to Placebo in Subjects With Diabetic Neuropathic Pain

NCT01579279 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

INDUSTRY

Sponsor class

Stopped Study Stopped

Conditions

Diabetic Neuropathic Pain

Interventions

DRUG: ABT-652 6 mg
DRUG: ABT-652 12 mg
DRUG: ABT-652 12 mg - 18 mg
DRUG: Placebo
DRUG: Duloxetine

Sponsor

AbbVie (prior sponsor, Abbott)